Study of Proteins and Metabolites in Body Fluids of People With Narcolepsy to Understand the Disease and Its Treatment

What This Trial Is About

Narcolepsy is a rare chronic disorder affecting the central nervous system, commonly seen in children and adolescents but less so in adults. It is characterized by excessive daytime sleepiness, sudden muscle weakness cataplexy, sleep paralysis, and hallucinations during sleep. Symptoms may also include increased appetite, weight gain, fragmented sleep, anxiety, and depression. Due to its varied symptoms, narcolepsy is often misdiagnosed. This research aims to explore changes in body fluid proteins and metabolites in narcolepsy patients to better understand the diseases underlying causes. The study involves comparing proteomics and metabolomics profiles of body fluids, including blood, urine, stool, and cerebrospinal fluid, from narcolepsy patients and healthy volunteers. Samples from narcolepsy patients will be analyzed both before and after drug treatment to identify potential molecular markers. Healthy volunteers will provide blood, urine, and stool samples but not cerebrospinal fluid. Samples will be collected in the same season and time period to ensure consistency. Participants will undergo detailed data collection, including medical history, sleep assessments using scales like the Epworth Sleepiness Scale and Pittsburgh Sleep Quality Index, and diagnostic sleep tests such as overnight polysomnography and multiple sleep latency tests. These evaluations help confirm diagnosis and measure sleepiness objectively. Researchers will analyze the molecular data alongside clinical information to identify markers related to narcolepsys biological features and prognosis. The study is expected to continue until 2027, with data carefully managed and statistically analyzed throughout.

Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy